NICE faces legal challenge over restriction on dementia drugsBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.39041.497315.DB (Published 23 November 2006) Cite this as: BMJ 2006;333:1085
- Clare Dyer, legal correspondent
The National Institute for Health and Clinical Excellence (NICE), the body that decides what treatments are supplied on the NHS in England and Wales, is facing a High Court challenge to its decision to restrict the use of drugs for Alzheimer's disease.
NICE rejected an appeal by drug companies in October over its guidance stating that patients with early or late stage Alzheimer's disease should not have access to donepezil (Aricept), galantamine (Reminyl), or rivastigmine (Exelon) (BMJ 2006;333:165).
The US drug company Pfizer and a Japanese biotechnology company, Eisai, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial